



# NEXT-GENERATION MEDICAL AI: BEYOND EXPERTS AND HYBRID ENHANCED

汇报人: 利友诚



# Large-scale pancreatic cancer detection via non-contrast CT and deep learning

nature medicine



“医疗AI多癌早筛公益项目”落户浙江丽水  
一次平扫CT 筛查多种癌症 (大健康观察)

本报记者 熊建

《人民日报海外版》(2024年02月27日 第09版)

Article

<https://doi.org/10.1038/s41591-023-02640-w>

## Large-scale pancreatic cancer detection via non-contrast CT and deep learning

Received: 9 February 2023

Accepted: 12 October 2023

Published online: 20 November 2023

Check for updates



Kai Cao<sup>1,19</sup>, Yingda Xia<sup>2,19</sup>, Jiawen Yao<sup>3,4,19</sup>, Xu Han<sup>5,19</sup>, Lukas Lambert<sup>6,19</sup>, Tingting Zhang<sup>7,19</sup>, Wei Tang<sup>8,19</sup>, Gang Jin<sup>9</sup>, Hui Jiang<sup>10</sup>, Xu Fang<sup>1</sup>, Isabella Nogues<sup>11</sup>, Xuezhou Li<sup>1</sup>, Wenchao Guo<sup>3,4</sup>, Yu Wang<sup>3,4</sup>, Wei Fang<sup>3,4</sup>, Mingyan Qiu<sup>3,4</sup>, Yang Hou<sup>12</sup>, Tomas Kovarnik<sup>13</sup>, Michal Vocka<sup>14</sup>, Yimei Lu<sup>9</sup>, Yingli Chen<sup>9</sup>, Xin Chen<sup>15</sup>, Zaiyi Liu<sup>15</sup>, Jian Zhou<sup>16</sup>, Chuanmiao Xie<sup>16</sup>, Rong Zhang<sup>16</sup>, Hong Lu<sup>17</sup>, Gregory D. Hager<sup>18</sup>, Alan L. Yuille<sup>18</sup>, Le Lu<sup>2</sup>, Chengwei Shao<sup>1</sup>✉, Yu Shi<sup>12</sup>✉, Qi Zhang<sup>5</sup>✉, Tingbo Liang<sup>5</sup>✉, Ling Zhang<sup>2</sup>✉ & Jianping Lu<sup>1</sup>✉





图为周永进正在检查患者的CT片。  
阿里巴巴达摩院供图

汇报人: 利友诚




# Introduction



## 胰腺癌



衰减的程度取决于器是的大小和类别



不同排数CT检查比较

	平扫	强化	联合强化	常规血管	心脏(冠脉)	灌注	能谱
16排CT	✓	✓	-	图像质量较差	-	-	-
64排CT	✓	✓	小范围联合	图像质量好	心率70以下	4cm灌注	-
超高端CT	✓	✓	大范围联合	多部位联合	任意心率成像	单器官灌注	✓



# Background and Contribution

---

## Background

Pancreatic ductal adenocarcinoma (PDAC) is **the most lethal solid malignancy**, often diagnosed at an advanced stage and unsuitable for surgery.

## Early detection, early intervention.

However, due to the relatively low incidence of PDAC, effective screening in the general population requires **high sensitivity and specificity** to minimize the risk of overdiagnosis.


Challenge: **Non-contrast computed tomography (CT)** holds the potential for large-scale screening; however, the identification of PDAC using non-contrast CT has long been considered impossible, while **enhanced CT** is prohibitively expensive and has associated side effects on the body.

Contribution: An artificial intelligence-based system called Pancreatic Cancer Detection with Artificial Intelligence (**PANDA**) has been proposed for the detection and classification of pancreatic lesions **using non-contrast CT**. When combined with non-enhanced CT, PANDA is comparable to the use of enhanced CT in distinguishing common subtypes of pancreatic lesions.




# Introduction


**a**



**b**



**c**




## Stage 1 (Pancreas Localization):

Due to the typically small area of pancreatic lesions in CT scans, localizing the pancreas can expedite the process of lesion detection, eliminating irrelevant information and enabling focused training on the pancreatic region.

### Method:

The input image size is (224, 192, 56). nnU-Net is employed for image segmentation, and the pancreatic region of the CT scan is extracted. It is then resized to a fixed size of (160, 256, 40) to enable more fine-grained classification and prediction of the CT scan.





# PANDA

## Stage 2 (Lesion Detection):

The purpose of this stage is to **detect lesions (PDAC/Non-PDAC) versus normal tissue.**

### Method:

Using nnU-Net for further image segmentation, specifically segmenting the lesions. Additionally, multiple scale pooling layers are incorporated into the model to predict the probability of the presence of lesions.




# PANDA

## Stage 3 (Differential Diagnosis):

The goal of the third stage is to **differentiate between different types of pancreatic lesions**, which are classified into eight subtypes: PDAC, PNET, SPT, IPMN, MCN, chronic pancreatitis, SCN, and others.

### Method:

The image is further segmented using nnU-Net to separate the lesions into **pancreatic tissue, PDAC, and Non-PDAC regions**. Additionally, the model incorporates learnable memory tokens and learnable positional encodings for cross-layer sharing.





1. **Lesion detection:** This task involves distinguishing lesions from normal tissue, including detection rates based on lesion type and cancer stage.
2. **Primary diagnosis:** This task focuses on differentiating PDAC from non-PDAC lesions and normal tissue. It also includes evaluating PDAC identification compared to non-PDAC + normal cases.
3. **Differential diagnosis:** This task involves classifying PDAC and seven subtypes of non-PDAC lesions.


# Evaluation

Sensitivity ( 敏感性 ), Specificity ( 特异性 ), AUC


Pred/GT		Ground Truth		Total		
		True	False			
Diagnosis	Pos.	TP	FP	prediction positive=TP+FP	PPV=TP/prediction positive, <b>Precision</b>	FDR=FP/prediction positive
	Neg.	FN	TN	prediction negative=FN+TN	FOR=FN/prediction positive	NPV=TN/prediction positive
合计		condition positive=TP+FN	condition negative=FP+TN	N=TP+FN+FP+TN		
		TPR=TP/condition positive, <b>Sensitivity, Recall</b>	FPR=FP/condition negative, <b>1-Specificity</b>			
		FNR=FN/condition positive, <b>1-Sensitivity</b>	TNR=TN/condition negative, <b>Specificity</b>			

# Internal Evaluation & External Evaluation


## Lesion Detection




## PDAC Identification



## American Joint Committee on Cancer (AJCC) T staging




## TNM(tumor, nodes, metastasis) staging




# Internal Evaluation & External Evaluation

## External evaluation centers



Confusion matrix for the external validation cohort.




Identification of lesions in different lesion subtype.

Confusion matrix for the internal validation cohort.




# Internal Evaluation & External Evaluation



**a** Internal Test Cohort (n=291)





External Test Cohorts (n=5,337)



**c**





**b**






**d**


Internal Differential Diagnosis Cohort (n=786)



# Reader Studies








f






# Lesion Detection on Chest CT







# Lesion Detection on Chest CT

f




# Real-World Study





# Case Study

**Month 0**  
Physical exam chest CT




**Standard of Care (SOC)**

Initial SOC → No pancreatic lesion reported ❌

**PANDA screen-detected PNET**


Data collection

**Month 7**  
Real-world clinical study



PANDA

PANDA detected ✓  
NonPDAC: probability 95%



MDT review → Recall for contrast MRI

**Month 7**

MR检查报告单

姓名: \*\*\*\* 性别: \*\* 年龄: \*\* 申请医生: \*\*\*\*  
病人编号: \*\*\*\* 检查编号: \*\*\*\* 检查类型: 特检 就诊编号: \*\*\*\*  
检查部位: 胰腺MR平扫+增强  
检查项目: 胰腺MR平扫+增强

所见:  
胰腺大小形态未见明显异常, 胰管未见扩张, 胰尾部可见一大小约1.2\*0.8cm T1低T2高信号, 与主胰管走行相平行, 增强扫描以动脉期最佳, 肝内多发大小不等无强化液性灶, 肝内胆管未见扩张, 胆囊不大, 胆囊壁厚, 胆囊未见异常, 脾脏不大, 脾脏未见异常, 双侧肾上腺未见异常信号, 双侧肾上腺未见异常信号, 未见腹水。

印象:  
胰尾局限性占位, 考虑神经内分泌肿瘤可能性大, 请结合临床  
肝内多发囊肿  
胆囊未见异常

**MRI report conclusion: consider PNET**

MDT recommends for surgery → Patient consent for surgery

**Month 7**  
Successful minimally invasive surgery


Pathology report 医院病理科  
病理诊断报告单 (已审核)

姓名	性别	年龄	病理号
任克平	男	52	20230101
手术医院	送检材料	胰腺+脾	

Max diameter 1.5cm

6-month follow up

**Month 13**



**MRI report conclusion: no relapse, no metastasis**

# Reader Experience

Reader ID	Experience (yr)	CT read per year	Pancreatic CT read per year	Traning/Expertise					
Specialist 1 (S1)	17	7,500	950	Pancreatic radiology	Resident 1 (R1)	2	4,500	300	General radiology
Specialist 2 (S2)	14	3,000	550	Pancreatic radiology	Resident 2 (R2)	3	5,000	350	General radiology
Specialist 3 (S3)	14	15,000	1,500	Pancreatic radiology	Resident 3 (R3)	2	1,000	200	General radiology
Specialist 4 (S4)	7	20,000	2,000	Pancreatic radiology	Resident 4 (R4)	2	12,000	1,000	General radiology
Specialist 5 (S5)	7	12,000	460	Pancreatic radiology	Resident 5 (R5)	2	500	100	General radiology
Specialist 6 (S6)	7	12,000	1000	Pancreatic radiology	Resident 6 (R6)	4	6500	200	General radiology
Specialist 7 (S7)	9	7500	340	Pancreatic radiology	Resident 7 (R7)	2	300	100	General radiology
Specialist 8 (S8)	12	11,000	450	Pancreatic radiology	Resident 8 (R8)	8	12,000	350	General radiology
Specialist 9 (S9)	13	16,565	2600	Pancreatic radiology	Resident 9 (R9)	4	6000	200	General radiology
Specialist 10 (S10)	8	15,000	560	Pancreatic radiology	Resident 10 (R10)	2	1200	100	General radiology
Specialist 11 (S11)	8	8000	1000	Pancreatic radiology	Resident 11 (R11)	4	6000	200	General radiology
General 1 (G1)	13	3,000	150	General radiology	Specialist 12 (S12)	6	16,000	400	Pancreatic radiology
General 2 (G2)	31	5,000	300	General radiology	Specialist 13 (S13)	7	17,000	400	Pancreatic radiology
General 3 (G3)	9	13,000	200	General radiology	Specialist 14 (S14)	7	15,000	500	Pancreatic radiology
General 4 (G4)	9	3800	170	General radiology	Specialist 15 (S15)	12	17,000	2,000	Pancreatic radiology
General 5 (G5)	8	1,800	100	General radiology	Specialist 16 (S16)	8	25,000	500	Pancreatic radiology
General 6 (G6)	8	20,000	500	General radiology	Specialist 17 (S17)	10	17,000	1,000	Pancreatic radiology
General 7 (G7)	8	1500	100	General radiology	Specialist 18 (S18)	6	23,000	500	Pancreatic radiology
General 8 (G8)	10	15,000	300	General radiology	Specialist 19 (S19)	12	20,000	2,000	Pancreatic radiology
General 9 (G9)	9	3200	150	General radiology	Specialist 20 (S20)	12	30,000	3,000	Pancreatic radiology
General 10 (G10)	10	18,000	200	General radiology	Specialist 21 (S21)	6	17,000	400	Pancreatic radiology
General 11 (G11)	9	3000	150	General radiology	Specialist 22 (S22)	7	15,000	1,000	Pancreatic radiology
					Specialist 23 (S23)	19	20,000	450	Pancreatic radiology
					Specialist 24 (S24)	10	20,000	450	Pancreatic radiology
					Specialist 25 (S25)	10	20,000	500	Pancreatic radiology
					Specialist 26 (S26)	10	21,000	500	Pancreatic radiology



The good generalizability of PANDA can be attributed to the following factors:

1. Training data from large tertiary hospitals, covering **diverse representations** of the Chinese population.
2. Non-contrast CT scans may be more universal for AI models compared to contrast-enhanced CT scans.
3. Integration of segmentation (capturing local pathological basis) and classification reduces the risk of overfitting in pure classification-based AI models.
4. The model was fine-tuned to achieve reliable control of false positives, with a specificity of 99% in the cross-validation process on a large training set (n=3,208).
5. Specificity was further improved to 99.9% by fine-tuning on false positives from external centers and the real world (tune on RW1 and val on RW2).
6. Regarding training data, **similar CT imaging protocols (e.g., slice thickness, CT dose index, oral contrast)** were used for cases and controls, forcing the model to focus on the primary learning objectives rather than fitting shortcuts or confounding factors.



# AI-based pathology predicts origins for cancers of unknown primary

nature

[Explore content](#) ▾ [About the journal](#) ▾ [Publish with us](#) ▾

[nature](#) > [articles](#) > article

Article | Published: 05 May 2021

## AI-based pathology predicts origins for cancers of unknown primary

[Ming Y. Lu](#), [Tiffany Y. Chen](#), [Drew F. K. Williamson](#), [Melissa Zhao](#), [Maha Shady](#), [Jana Lipkova](#) & [Faisal Mahmood](#) 

[Nature](#) **594**, 106–110 (2021) | [Cite this article](#)


**38k** Accesses | **246** Citations | **416** Altmetric | [Metrics](#)

汇报人: 利友诚



1. **The site of a primary tumor** is crucial for guiding clinical care in metastatic cancer cases.
2. Determining the site of origin is challenging despite histopathological examination and clinical/radiological assessments.
3. Cancers categorized as CUPs (Cancer of Unknown Primary) account for 1–2% and lack a definitive primary origin.
4. Comprehensive diagnostic work-ups are performed for CUP patients, but empirical chemotherapy is usually administered due to the lack of primary site identification.
5. **Genomics and transcriptomics** have been proposed to identify the primary origin, but molecular profiling is not routinely conducted, especially in low-resource settings.
6. Uncertainty in classifying tumors as primary or metastatic and misdiagnosing relapse are reported in the literature.

# TOAD workflow


## Train



## Test











## Multiclass, multitask, multiple-instance learning






# Results



# Discussion

Human Doctor



吕乐 医学CV科学家 IEEE Fellow TPAMI副主编

这个真的不是为了替代医生 这个人工智能跟医生是可以重新构造一个新的临床流程 并不是想象的这么直接暴力 通过大数据把医生替换掉 医疗里面，整个流程是很复杂的 真正想把病人服务好照顾好的事情 里面很复杂 要把整个流程跑通 真正对病人好 里面有很多人工智能做的事情，也有很多医生要做的事情 如何看待全国首个「医疗AI多癌早筛」项目正式项目落地，「医疗+AI」模式给癌症治疗带来哪些帮助？


发布于 2024-02-25 10:02

8人喜欢 1条评论 分享 收藏 举报

收起



Medical AI



Interpretable Model/Interface

Attention Map

1. Pancreatic Cancer Detection; (HARD)
2. Breast Cancer Diagnosis; (HARD)
3. CUP Diagnosis; (REALLY HARD)
4. Alzheimer's Early Detection; (REALLY HARD) ...

Beyond Experts

Mixture of AI-Experts

Challenge: Misleading & Trust  
Why AI can assist doctors in diagnosis?  
How does AI assist doctors in diagnosis?  
Why do we trust **senior doctors** more?

Hybrid Enhanced

AI assist Human Doctors > AI and Human Doctors

Interpretability

Task

Pulmonary Nodule Localization


Engineering

Target


Events




2017



2021



2023



202X

思想自由 兼容并包

Related Files



Closed Environment



Medical Diagnosis is not a GAME



# Q&A

汇报人：利友诚